# Hidradenitis Suppurativa and Treatments

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/hidradenitis-suppurativa-and-treatments/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the treatment, pathogenesis, and comorbidities of Hidradenitis Suppurativa (HS), also known as Acne Inversa. It covers topics such as inflammatory pathways, genetic susceptibility, metabolic syndrome, and the impact of HS on quality of life. The cluster also discusses various therapeutic approaches including immunosuppressive therapy and TNF-alpha inhibitors. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t12731 |
| Works | 86 |

## Topic papers all

Showing 15 of 86.

- [Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial](https://scholariq.org/papers/expanded-allogeneic-adipose-derived-mesenchymal-stem-cells-cx601-for-complex/)
- [Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial](https://scholariq.org/papers/adalimumab-therapy-for-moderate-to-severe-psoriasis-a-randomized-controlled/)
- [Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis](https://scholariq.org/papers/phase-3-studies-comparing-brodalumab-with-ustekinumab-in-psoriasis/)
- [Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa](https://scholariq.org/papers/two-phase-3-trials-of-adalimumab-for-hidradenitis-suppurativa/)
- [Hidradenitis suppurativa](https://scholariq.org/papers/hidradenitis-suppurativa-2/)
- [Obesity and the skin: Skin physiology and skin manifestations of obesity](https://scholariq.org/papers/obesity-and-the-skin-skin-physiology-and-skin-manifestations-of-obesity/)
- [Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis](https://scholariq.org/papers/risankizumab-versus-ustekinumab-for-moderate-to-severe-plaque-psoriasis/)
- [The prevalence of hemorrhoids in adults](https://scholariq.org/papers/the-prevalence-of-hemorrhoids-in-adults/)
- [Comparison of hemorrhoidal treatment modalities](https://scholariq.org/papers/comparison-of-hemorrhoidal-treatment-modalities/)
- [Hidradenitis suppurativa](https://scholariq.org/papers/hidradenitis-suppurativa/)
- [Development and validation of the International Hidradenitis Suppurativa Severity Score System ( <scp>IHS</scp> 4), a novel dynamic scoring system to assess <scp>HS</scp> severity](https://scholariq.org/papers/development-and-validation-of-the-international-hidradenitis-suppurativa/)
- [Community differentiation of the cutaneous microbiota in psoriasis](https://scholariq.org/papers/community-differentiation-of-the-cutaneous-microbiota-in-psoriasis/)
- [Diagnostic delay in hidradenitis suppurativa is a global problem](https://scholariq.org/papers/diagnostic-delay-in-hidradenitis-suppurativa-is-a-global-problem/)
- [Hidradenitis Suppurativa/Acne Inversa: Criteria for Diagnosis, Severity Assessment, Classification and Disease Evaluation](https://scholariq.org/papers/hidradenitis-suppurativa-acne-inversa-criteria-for-diagnosis-severity-assessment/)
- [The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside](https://scholariq.org/papers/the-il-23-il-17-pathway-in-inflammatory-skin-diseases-from-bench-to-bedside/)

## Topic primary papers

Showing 15 of 38.

- [Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa](https://scholariq.org/papers/two-phase-3-trials-of-adalimumab-for-hidradenitis-suppurativa/)
- [Hidradenitis suppurativa](https://scholariq.org/papers/hidradenitis-suppurativa-2/)
- [Hidradenitis suppurativa](https://scholariq.org/papers/hidradenitis-suppurativa/)
- [Development and validation of the International Hidradenitis Suppurativa Severity Score System ( <scp>IHS</scp> 4), a novel dynamic scoring system to assess <scp>HS</scp> severity](https://scholariq.org/papers/development-and-validation-of-the-international-hidradenitis-suppurativa/)
- [Diagnostic delay in hidradenitis suppurativa is a global problem](https://scholariq.org/papers/diagnostic-delay-in-hidradenitis-suppurativa-is-a-global-problem/)
- [Hidradenitis Suppurativa/Acne Inversa: Criteria for Diagnosis, Severity Assessment, Classification and Disease Evaluation](https://scholariq.org/papers/hidradenitis-suppurativa-acne-inversa-criteria-for-diagnosis-severity-assessment/)
- [Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials](https://scholariq.org/papers/secukinumab-in-moderate-to-severe-hidradenitis-suppurativa-sunshine-and-sunrise/)
- [Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa](https://scholariq.org/papers/safety-and-efficacy-of-anakinra-in-severe-hidradenitis-suppurativa/)
- [Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization – systematic review and recommendations from the HS ALLIANCE working group](https://scholariq.org/papers/hidradenitis-suppurativa-acne-inversa-a-practical-framework-for-treatment/)
- [Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment](https://scholariq.org/papers/hidradenitis-suppurativa-from-pathogenesis-to-diagnosis-and-treatment/)
- [Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa](https://scholariq.org/papers/evidence-based-approach-to-the-treatment-of-hidradenitis-suppurativa-acne/)
- [Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment](https://scholariq.org/papers/assessing-the-validity-responsiveness-and-meaningfulness-of-the-hidradenitis/)
- [Cardiovascular disease risk factors in patients with hidradenitis suppurativa: a systematic review and meta-analysis of observational studies](https://scholariq.org/papers/cardiovascular-disease-risk-factors-in-patients-with-hidradenitis-suppurativa-a/)
- [What causes hidradenitis suppurativa ?—15 years after](https://scholariq.org/papers/what-causes-hidradenitis-suppurativa-15-years-after/)
- [Evidence for a ‘window of opportunity’ in hidradenitis suppurativa treated with adalimumab: a retrospective, real‐life multicentre cohort study*](https://scholariq.org/papers/evidence-for-a-window-of-opportunity-in-hidradenitis-suppurativa-treated-with/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.